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Abstract 
Deregulation of proliferation and differentiation-dependent signalling pathways 
is a hallmark of human papillomavirus (HPV) infection. Although the 
manipulation of these pathways by E6 and E7 has been extensively studied, 
controversies surround the role of the E5 oncoprotein during a productive 
virus life cycle. By integrating primary keratinocytes harbouring wild type or E5 
knockout HPV18 genomes with pharmacological and gain/loss of function 
models, this study aimed to provide molecular information about the role of E5 
in epithelial proliferation and differentiation. We show that E5 contributes to 
cell cycle progression and unscheduled host DNA synthesis in differentiating 
keratinocytes. E5 function correlates with increased EGFR activation in 
differentiating cells and blockade of this pathway impairs differentiation-
dependent cell cycle progression of HPV18 containing cells. Our findings 
provide a functional requirement of enhanced EGFR signalling for suprabasal 
cellular DNA synthesis during the virus life cycle. They also reveal an 
unrecognised contribution of E5 towards the impaired keratinocyte 
differentiation observed during a productive HPV infection. E5 suppresses a 
signalling axis consisting of the keratinocyte growth factor receptor (KGFR) 
pathway. Inhibition of this pathway compensates for the loss of E5 in knockout 
cells and re-instates the delay in differentiation. The negative regulation of 
KGFR involves suppression by the EGFR pathway. Thus our data reveal an 
unappreciated role for E5-mediated EGFR signalling in orchestrating the 
balance between proliferation and differentiation in suprabasal cells.  
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Introduction 
Human papillomaviruses (HPV) infect the squamous epithelial cells at a 
number of body sites [1,2]. A small number of HPV types are carcinogenic 
and recognized as the agent for most anogenital cancers and a subset of 
cancers of the oropharyngeal tract, with HPV16 and HPV18 being responsible 
for the largest incidence of cervical cancer [3,4].   
Keratinocyte homeostasis is controlled by the complex interplay of signalling 
pathways functioning in an integrated fashion. In the basal compartment, 
epidermal growth factor receptor (EGFR) signalling is a major determinant of 
keratinocyte proliferation by promoting cell cycle progression [5]. Tissues 
lacking key components of the EGFR signalling pathway including 
ERK/MAPK are hypoproliferative and display G2/M arrest [5]. In addition to 
increasing proliferation, EGFR signalling suppresses keratinocyte 
differentiation [6]. This is required to maintain homeostasis between self-
renewing and committed keratinocytes in the basal proliferative compartment 
of the epidermis, whereas in the upper layers this pathway is down regulated. 
Once a keratinocyte enters the suprabasal layer, it induces expression of 
proteins involved in the sequential programme of terminal differentiation [7]. 
Whilst there is not a complete understanding of the pathways that orchestrate 
differentiation, a number of critical regulators of this process are recognized 
including the keratinocyte growth factor receptor (KGFR/FGFR2IIIb). This is 
expressed in suprabasal layers and induces gene expression changes 
associated with terminal differentiation. KGFR over-expression in basal cells 
induces premature expression of spinous layer associated markers, whilst 
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ablation, by genetic or chemical means, results in a hyperproliferative 
epidermis [8,9].  
The HPV life cycle is linked to differentiation of the epithelial tissues they 
infect. Following infection of keratinocytes in the epithelial basal layer, HPV 
genomes are established as episomes. After a mitotic event, infected basal 
cells migrate towards the suprabasal regions and begin to differentiate. In 
contrast to uninfected keratinocytes, when the infected basal cells detach 
from the basement membrane they fail to undergo the early stages of 
differentiation and re-enter the cell cycle in the suprabasal layers to enable 
the virus episomes to be amplified to a high copy number [1]. In the upper 
layers of the epithelium, infected cells exit the cell cycle and re-enter the 
differentiation process, enabling transit to the late stage of infection, where the 
late promoter is activated to drive expression of the structural proteins in 
preparation for packaging of the viral genome into newly synthesized capsids.   
High-risk HPV genomes encode three early genes (E5, E6 and E7), classed 
as oncogenes that manipulate the host cell environment by influencing cell 
proliferation, differentiation and survival. E6 and E7 are the major drivers of 
keratinocyte proliferation and their expression is retained in cancers. They are 
required for immortalization of keratinocytes and their best understood 
functions are to inactivate p53 and pRb tumour suppressor proteins [10,11]. In 
contrast, E5 remains one of the least understood of the early proteins [12]. E5 
is a membrane-integrated protein [12,13] presumed to localize to the 
endoplasmic reticulum and Golgi apparatus [14]. Efforts to understand the 
contribution of E5 to HPV pathogenesis have shown that it induces 
anchorage-independent growth in murine fibroblasts and growth in low serum 
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[15,16], whilst demonstrating weak transforming activity in primary human 
keratinocytes [17]. Several studies have shown that E5 potentiates EGFR 
signalling, and modulation of this pathway is implicated in its transforming 
ability [12,18]. Transgenic mouse models expressing HPV16 E5 in the 
epithelium display hyperplasia, resulting in spontaneous tumour formation 
[19]. These mice also display increased dysplastic disease in the cervical 
epithelium [20]. Importantly, the epithelial hyperplasia induced by E5 is 
attenuated when the EGFR pathway is inhibited by expression of a dominant 
negative EGFR [19]. In cervical cancers HPV genomes are regularly 
integrated into host DNA, and this occurs such that the E5 gene is often lost. 
This suggests that E5 plays a critical role in the genesis of cervical cancer but 
less of a role in its progression or persistence.   
Studies of E5 function in high-risk HPV16 [21] and HPV31 [22] life 
cycle models show that E5 function is likely not required by the virus in 
undifferentiated cells, but does play a role during the productive stages of 
infection in the differentiated epithelium. They highlight a need for E5 in 
regulating host cell cycle progression and aiding virus genome amplification. 
Despite these advances, the mechanisms by which E5 regulates these 
processes are unknown [23,24]. Interestingly, neither study identified any 
differences in suprabasal differentiation in the absence of E5. These findings 
are disputed by more recent in vivo studies, highlighting a role for E5 in the 
deregulation of differentiation in the epithelia of the HPV16 transgenic mouse 
[19]. Subtle differences are also observed in the requirement for E5 between 
the two HPV types tested. These might relate to differences in experimental 
design, or the use of immortalized keratinocytes to study HPV16 versus 
Wasson  E5 and the HPV18 life cycle 
	 6	
primary keratinocytes to test HPV31. Alternatively, they may relate to genuine 
type specific differences in the role of E5. Finally, no apparent role for EGFR 
signalling was identified in either model, which is distinct from evidence 
supporting manipulation of this pathway in cells expressing E5, or the 
requirement for EGFR in E5-mediated transformation shown in the transgenic 
mouse model.   
Given these disparities and the possibility of HPV type specific 
differences in E5 function, we examined the role of E5 in the HPV18 life cycle 
utilizing a primary human keratinocyte model system [25-27]. We confirm that 
loss of E5 function impacts on the productive stages of the virus life cycle and 
impairs maintenance of the cell cycle upon keratinocyte differentiation. We 
provide new evidence highlighting a role for E5 in impairing keratinocyte 
differentiation. At the biochemical level, E5 suppresses the KGFR pathway, 
whilst enhancing proliferative signalling. Use of small molecule inhibitors and 
expression of mutant signalling proteins affirms that keratinocyte 
differentiation requires an integrated signalling response with significant cross 
talk between pathways. In particular, attenuation of EGFR signalling impacted 
on all pathways studied. These data indicate that E5 subverts EGFR 
signalling as a unifying mechanism to alter proliferation and differentiation 
pathways in keratinocytes. 
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Results 
Loss of E5 expression does not alter HPV18 genome establishment in 
undifferentiated primary human keratinocytes. To study the role of E5 in 
the HPV18 life cycle, we generated a mutant HPV18 genome in which the E5 
open reading frame was disrupted by the introduction of a translation 
termination codon. This mutant, HPV18 E5KO, contains a single nucleotide 
change at position 3940, inserting a translational stop codon at position 2 in 
the E5 sequence. The mutation would not be expected to interfere with any of 
the splice sites recently identified in the HPV18 genome [23,28]. Wild type 
(WT) and E5KO (KO) HPV18 genomes were transfected into low passage 
neonate normal human keratinocytes (NHK) obtained from two individual 
foreskin donors. Southern blotting of total genomic DNA isolated from 
undifferentiated monolayer cultures showed that the WT and E5KO viral 
genomes were established as extra-chromosomal episomes (Fig. 1A). Whilst 
minor differences exist in absolute genome copy number per cell in each 
donor, no significant differences were observed between the WT (donor 1: 
172 and donor 2: 208) and E5KO (donor 1: 168 and donor 2: 194) genome-
containing cells. After serial passaging of the cell lines (average population 
doubling times: WT, 34 hours; E5KO, 31 hours) the HPV18 episomes were 
maintained in the absence of E5 protein (data not shown). Whilst no antibody 
exists to detect E5, to ensure that the mutagenesis strategy did not adversely 
affect E6 and/or E7 expression, the levels of the two oncoproteins were 
assessed in lysates from cells cultured in high calcium media for over 72 
hours (Fig. 1B). Levels of both oncoproteins were highest in undifferentiated 
WT and E5KO cells and upon differentiation the levels of both proteins 
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declined. Importantly, there was little variation of either oncoprotein between 
WT and E5KO cell lines under study.  
 
E5 supports cell cycle re-entry of post-mitotic suprabasal keratinocytes.  
Given a lack of requirement for E5 function in the early stages of the HPV18 
life cycle we investigated its role during the differentiation-dependent stage of 
the infectious cycle. At this stage, the virus is required to re-establish cell 
cycle progression in the post-mitotic suprabasal cells to stimulate 
unscheduled host cell DNA synthesis to provide an environment conducive to 
virus genome amplification. To investigate the effect of E5 function on host 
DNA replication, HPV18 genome-containing lines were stratified in 
organotypic raft cultures for 13 days and the thymidine analogue 
bromodeoxyuridine (BrdU) was incorporated over the final 16 hours before 
fixation. The percentages of BrdU-positive cells present in the raft cultures 
were then quantified. As expected, BrdU-positive cells were confined to the 
basal layer in NHK-derived rafts, whereas BrdU-positive nuclei were detected 
in both the basal and suprabasal compartments of WT and E5KO genome 
containing cells (Fig. 1C). Quantification of the number of BrdU positive nuclei 
revealed no significant differences in BrdU staining in the basal layers in 
E5KO cells compared to WT (Figure 1C & D). In contrast, a statistically 
significant decrease in BrdU staining was observed in the suprabasal layers in 
the E5KO rafts, which was consistent between donors (Figure 1C & D). 
Despite the decrease in DNA synthesis observed in the E5KO rafts, this did 
not equate to gross morphological changes in the rafts as observed in 
haematoxylin and eosin stained sections (Figure 1C). 
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Recent observations suggest that HPV DNA amplification occurs in 
suprabasal cells that have entered a protracted G2 phase of the cell cycle 
[29]. Cells in G2 are identified by cytoplasmic cyclin B1 expression; the cyclin-
cdk complex is retained in the cytoplasm in an inactive form and must first be 
dephosphorylated prior to the nuclear translocation observed during mitosis. 
To determine if E5 function was necessary for progression of the viral 
genome-containing cells through to G2, cyclin B1 expression was assessed.  
Cytoplasmic cyclin B1 was restricted to the basal layer of NHK raft cultures 
(Fig. 2A). In the WT and E5KO cultures, cytoplasmic cyclin B1 was detected 
in the basal and suprabasal layers (Fig. 2A & B). Whilst levels of cyclin B1 
positive stained cells in the basal layer did not differ, we observed a significant 
loss of cyclin B1 staining in the suprabasal layers of the E5KO rafts (Fig. 2A & 
B).  
These data were confirmed in cells differentiated in high calcium media 
for 72 hours. Cyclin B1 levels declined rapidly in differentiated NHK (Fig. 2C 
lanes 1-3). In accordance with observations from raft cultures cyclin B1 
expression persisted in differentiating keratinocytes harbouring HPV18 WT 
and E5KO cells (Fig. 2C lanes 4-6, 7-9). However, at 72 hours the level of 
cyclin B1 in the E5KO cells was significantly reduced compared to WT (Fig. 
2C; compare lanes 6 and 9) (Quantification in Fig. 2D). Taken together, these 
data suggest that E5 contributes to the maintenance of cell cycle activity in 
suprabasal cells.  
 
E5 is not necessary for HPV18 genome amplification or late viral protein 
expression in differentiating keratinocytes. Given that our data indicated a 
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decrease in the ability of cells containing the E5KO genomes to retain 
proliferative potential once exposed to differentiation stimuli, we examined 
viral genome amplification by chromogenic in situ hybridisation (CISH) using a 
HPV specific probe on raft sections. As shown in Figure 3A, intensely stained 
nuclei, corresponding to cells undergoing viral DNA amplification, were found 
in cells of the upper suprabasal layers of the rafts carrying WT and E5KO 
genomes. Quantification of the data did not show a significant difference in 
the number of cells undergoing viral genome amplification in the absence of 
E5 (Fig. 3A). These results indicate that whilst loss of E5 impacts on host 
suprabasal DNA synthesis, it does not make a significant contribution towards 
virus genome amplification.   
 Expression of the virus capsid proteins and the E4 protein occurs in the 
more differentiated cells of the epithelium. To determine if loss of E5 affected 
these hallmarks of the productive life cycle, rafts were stained with antibodies 
that recognise E4, an HPV protein that is up-regulated at the onset of viral 
genome amplification (Fig. 3B), and the major capsid protein L1 (Fig. 3C). In 
rafts of cells containing the WT genomes staining of E4 and L1 was observed 
in the upper suprabasal layers. No significant differences in the staining 
patterns were observed between WT and E5KO cells. Taken together, these 
data indicate that HPV18 E5 is not required for the expression of late viral 
proteins and concurs with previous findings from the HPV16 life cycle model 
lacking E5 expression [21].  
 
HPV18 E5 enhances EGFR expression in primary human keratinocytes. 
EGFR signalling is a major driver of proliferation in the basal compartment of 
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the epithelium [6]. It regulates the activity of downstream components such as 
ERK/MAPK, which are essential for G2/M progression in primary 
keratinocytes [5]. Expression of isolated E5 has been shown to augment 
EGFR expression and autophosphorylation, and to enhance mitogenic 
signalling [30]. To determine if the effects of E5 on the cell cycle progression 
of post mitotic keratinocytes was linked to an effect on EGFR signalling during 
the differentiation dependent life cycle, NHK and HPV18 genome-containing 
keratinocytes were stratified in raft culture and levels of total EGFR detected 
by immunofluorescence staining. EGFR expression was restricted to the 
basal cells in normal human keratinocytes (Fig. 4A). In contrast, WT genome 
containing rafts exhibited a marked increase in plasma membrane localised 
EGFR expression in the basal and suprabasal layers (Fig. 4A). E5KO rafts 
also displayed increased plasma membrane localised EGFR expression in the 
basal compartment, however, suprabasal EGFR expression was reduced 
compared to WT rafts (Fig. 4A). WT and E5KO rafts were digitally scanned 
from basal layer to the top and analysed by cross-sectional imaging analysis 
(Fig. 4B). No obvious difference was observed in the EGFR expression profile 
in the lower epithelial layers; however, this analysis clearly highlighted the 
loss of EGFR expression in the upper suprabasal layers of E5KO rafts (Fig. 
4B; highlighted by an arrow).  
EGFR levels were also determined by western blot of lysates from 
keratinocytes grown in high calcium media. In monolayer culture, NHK cells 
expressed low levels of EGFR, detectable only after longer exposure of the 
blot (Fig. 4C; lanes 1-3). In contrast, EGFR expression was substantially 
increased in undifferentiated keratinocytes harbouring either WT or E5KO 
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genomes compared to NHK (Fig. 4C; compare lanes 1, 4 and 7). Upon 
differentiation, the level of EGFR protein declined moderately but was still 
detectable at 72 h in WT containing keratinocytes (Fig. 4C; lanes 4-6). In the 
absence of E5, EGFR expression declined rapidly and was 90% lower than in 
WT cells at 72 h (Fig. 4C; compare lanes 6 and 9 – p<0.0007). These data 
demonstrate that E5 maintains the increase in EGFR expression observed in 
suprabasal cells, but is not required for increased EGFR in the basal layer of 
the epithelium.  
 
Active EGFR is needed for cyclin B1 expression in differentiating 
keratinocytes. Next we studied the contribution of EGFR-ERK MAPK 
signalling to the cyclin B1 expression observed in differentiated HPV18 
containing keratinocytes (Fig. 5A). WT cells were transfected with a pool of 
commercially available, validated siRNA to deplete EGFR expression or a 
scrambled control, and cells cultured in high calcium media for 48 hours to 
induce differentiation. As expected, WT cells transfected with the scrambled 
control retained EGFR expression upon differentiation (Fig. 5B; compare 
lanes 1 and 2). In contrast, transfection of the pool of EGFR specific siRNA 
resulted in a 50% reduction in EGFR levels in the differentiated cells (Fig. 5B; 
compare lanes 2 and 3). The reduction in EGFR protein expression correlated 
with a 40% decrease in ERK1/2 phosphorylation, indicating that the signalling 
pathway was impaired. Importantly, a decrease in cyclin B1 expression to 
similar levels as in the E5KO cells was observed (Fig. 5B; compare lanes 3 
and 5). To investigate whether an active EGFR kinase was necessary for the 
increased cyclin B1 expression, keratinocytes harbouring WT genomes were 
Wasson  E5 and the HPV18 life cycle 
	 13	
grown in high calcium media for 48 hours in the presence of 2 µM of a specific 
and highly potent small molecule inhibitor targeting the intracellular EGFR 
kinase domain (PD153035 - [31]) (Fig. 5C). Whereas the untreated WT cells 
retained cyclin B1 upon differentiation, cells treated with the EGFR inhibitor 
had reduced cyclin B1 expression similar to levels observed in the E5KO cells 
(Fig. 5C; compare lanes 2 and 3 plus 3 and 5). The reduction in cyclin B1 
expression correlated to reduced ERK1/2 phosphorylation, demonstrating that 
EGFR signalling was successfully inhibited (Fig. 5C; compare lanes 2 and 3).  
Similar results were observed with a specific small molecule inhibitor of 
Mek1/2 (UO126 – 20 µM - [32]), which inhibits activation of the ERK1/2 MAPK 
cascade (Fig. 5D). These results indicate that activation of EGFR is 
necessary for the differentiation-dependent cyclin B1 expression in HPV18 
genome containing cells. Notably, they also demonstrate that the blockade of 
this signalling pathway in cells harbouring the WT genomes lowers cyclin B1 
levels to those observed in cells that lack E5 expression.    
 
HPV18 E5 reduces keratinocyte differentiation.  Active EGFR is associated 
with a failure of differentiation in the epithelium. We hypothesized that 
enhanced EGFR expression might result in delayed keratinocyte 
differentiation. A defect in involucrin expression was observed in the E5KO 
cells by western blot of lysates from cells cultured in high calcium medium 
(Fig. 6). In NHK and E5KO cells the levels of involucrin had risen markedly by 
48 h growth in calcium, whereas in the WT cells levels of involucrin were 6-
fold lower at 48h (p<0.02) and high levels of expression were achieved only 
after 72 h growth (Fig. 6; compare lanes 2, 5 and 8). Similarly, levels of 
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another differentiation marker – cytokeratin 1 – were perturbed in WT versus 
E5KO containing cells (Fig. 6). These data indicate that E5 contributes to the 
HPV18 mediated suppression of epithelial differentiation.  	
Negative regulation of the keratinocyte growth factor receptor 
(KGFR/FGFR2IIIb) by HPV18 E5.  To understand the mechanisms by which 
E5 regulates keratinocyte differentiation, we focused on the KGFR/FGFR2IIIb 
pathway. KGFR is a splice variant of the fibroblast growth factor receptor 2 
(FGFR2IIIb) exclusively expressed in epithelial cells [33]. Reports have linked 
KGFR to skin homeostasis and as a regulator of the balance between 
proliferation and differentiation [9]. Mice lacking KGFR expression in skin 
epithelia display aberrant keratinocyte proliferation, impaired differentiation 
and are prone to the development of papilloma-like lesions [9]. First, levels of 
KGFR protein expression were examined by immunofluorescence staining in 
raft cultures (Fig. 7A-B). As expected, KGFR expression was restricted to the 
suprabasal layers of the epithelium (Fig. 7A and B). In NHK cells KGFR 
expression was only detected in the mid and upper suprabasal layers of the 
epithelium (Fig. 7A). Overall levels of KGFR protein were reduced in WT 
containing cells, whilst the E5KO rafts showed a KGFR expression profile 
more similar to that observed in the NHK cells, with abundant KGFR seen in 
the mid and upper suprabasal layers (Fig. 7A & B). HPV16 E5 has been 
suggested to impair KGFR transcription when overexpressed in HaCaT cells 
[34]. We were able to confirm that levels of KGFR mRNA were significantly 
lower in calcium differentiated WT compared to E5KO containing cells (Fig. 
7C).  
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EGFR signalling suppresses KGFR expression. The EGFR pathway has 
been proposed to function as an inhibitor of KGFR expression [6,35]. We 
tested whether KGFR expression could be repressed through EGFR 
signalling by treating cells harbouring WT genomes with the EGFR kinase 
inhibitor PD153035 over a 48 hour time course of differentiation with high 
calcium (Fig. 7D). Cells were then lysed and assayed by western blot for 
KGFR activation. Due to inadequate antibody reagents, the phosphorylated 
form of FRS2α,  a docking protein phosphorylated by the active form of 
KGFR, was used as a surrogate for active KGFR expression (Fig. 7D) [33]. 
Levels of P-FRS2α were higher in differentiated E5KO compared to WT 
lysates (Fig. 7E; compare lanes 2 and 5). Importantly, chemical inhibition of 
EGFR kinase activity (Fig. 7D; compare lanes 2 and 3) resulted in an increase 
in the phosphorylated form of FRS2α, which correlates with active KGFR 
signalling. 
 
KGFR signalling is impaired in cells harbouring HPV18 genomes. AKT is 
a master serine/threonine kinase, which acts as a major downstream effector 
of KGFR during keratinocyte differentiation. Upon KGFR mediated activation 
of phosphatidylinositol 3-kinase (PI3-kinase), and the subsequent generation 
of phosphatidylinositol 3,4,5-trisphosphate, AKT is recruited to the plasma 
membrane, where it is phosphorylated and activated [36]. AKT 
phosphorylates a number of substrates in the cytoplasm and nucleus 
associated with keratinocyte differentiation and survival e.g. GSK3β (Fig. 8A) 
[37,38]. To understand the implications of the loss of KGFR expression on 
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down-stream signalling pathways, we examined the expression and post-
translational modification of AKT in our HPV genome-containing cell lines 
upon differentiation in high calcium medium. The levels of total AKT 
diminished slightly upon differentiation, although they remained higher in 
HPV18 containing cells compared to NHK controls and the loss of E5 
expression did not impact on the increase in AKT (Fig. 8B; compare lanes 1, 3 
and 7). Whilst the level of total AKT protein decreased upon differentiation, 
there was a differentiation-dependent increase in Ser473 AKT 
phosphorylation in NHK cells (Fig. 8B; compare lanes 1 with 2 and 3). In 
contrast, the level of phosphorylated Ser473 AKT was substantially reduced in 
the WT containing cells, both in undifferentiated and in differentiated cells 
(Fig. 8B; compare lanes 1 and 4, 3 and 6). The loss of E5 protein reinstated 
the temporal pattern of differentiation-dependent AKT phosphorylation (14 fold 
increase in P-AKT in the E5KO compared to WT at 72h – p<0.02), although 
the level of phosphorylation was lower than in the NHK cells (Fig. 8B: 
compare lanes 1, 4 and 7 and 3, 6 and 9).  
A similar loss in the differentiation-dependent increase in GSK3β 
phosphorylation was observed in WT genome-containing cells (Fig. 8B; 
compare lanes 1-3 and 4-6). Again, E5KO cells recapitulated the pattern of 
GSK3β phosphorylation observed in NHK cells but to lower levels (Fig. 8B; 
compare lanes 1-3 with 7-9). Together these data indicate that HPV18 E5 
reduces differentiation-dependent AKT activation in keratinocytes.   
 
Pharmacological blockade of KGFR compensates for the loss of E5 and 
delays keratinocyte differentiation.  To investigate whether the failure of 
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E5KO cells to impair differentiation was due to an inability to down-regulate 
KGFR signalling, we determined whether pharmacological inhibition of the 
KGFR pathway might compensate for loss of E5. To inhibit KGFR kinase 
activity, E5KO cells were differentiated in the presence of PD173074 (30 nM), 
a potent small molecule inhibitor targeting FGFR2 kinases (Fig. 9A) [39]. We 
first confirmed the effects of PD173074 by assessing the phosphorylation 
status of the adaptor protein FRS2α. As expected, levels of FRS2α 
phosphorylation were greater in the E5KO cells upon differentiation compared 
to WT (Fig. 9B, compare lanes 2 and 4), indicating increased KGFR activity. 
The addition of PD173074 reduced the levels of FRS2α phosphorylation in 
the E5KO cells, and this effect correlated with a decrease in AKT 
phosphorylation and reduced expression of cytokeratin 1 (Fig. 9B).  
We were intrigued to test whether pharmacological blockade of KGFR 
might also increase cyclin B1 expression in the E5KO cells. Treatment with 
the KGFR inhibitor had no impact on cyclin B1 expression in the E5KO cells 
(Fig. 9B). This indicates that the E5 mediated increase in cyclin B1 expression 
is either upstream of KGFR repression or within a separate signalling network. 
We conclude that blockade of KGFR in cells harbouring HPV18 E5KO 
genomes rescues the differentiation phenotype associated with the absence 
of E5, but cannot prevent the reduction of cyclin B1 expression.  
 
AKT is essential for the E5-mediated reduction in keratinocyte 
differentiation.  Our data indicates that suppression of KGFR by E5 was 
necessary to reduce keratinocyte differentiation, and raised the possibility that 
the regulation of downstream components of KGFR signalling might be critical 
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for keratinocyte differentiation and the productive virus life cycle. One such 
effector is AKT, which plays a functional role in the construction of the 
suprabasal layers [38]. We sought to determine the contribution of AKT 
inhibition by E5 to keratinocyte differentiation (Fig. 10A). We asked whether a 
myristoylated form of AKT1 – the predominant isoform of AKT in human 
keratinocytes [38] – that is targeted to the membrane independently of PI3-
kinase activity could overcome the delay in early differentiation exhibited in 
keratinocytes harbouring HPV18 genomes. WT genome containing cells were 
transduced with a retrovirus encoding AKT1 containing an amino terminal HA 
epitope tag engineered to contain the myristoylation signal sequence from the 
c-Src tyrosine kinase [40], and subsequently cultured in high calcium 
containing media for 48 hours. Analysis of the protein lysates by western blot 
confirmed the low levels of the differentiation marker cytokeratin 1 in WT cells 
compared to those lacking E5 (Fig. 10B; compare lanes 2 and 5). In contrast, 
cells expressing constitutively active AKT1 overcame the HPV18 mediated 
block and expressed levels of cytokeratin 1 similar to the E5KO cell line (Fig. 
10B; compare lanes 2 and 3). Western blotting with an antibody recognizing 
the HA epitope confirmed expression of the exogenous AKT1 in the 
appropriate sample. 
If AKT is a critical host target for E5 function, then we anticipated that 
the introduction of a dominant negative form of this protein might compensate 
for the lack of E5 and delay keratinocyte differentiation (Fig. 10A). To test this, 
E5KO cells were transduced with a retrovirus encoding a kinase inactive 
version of the myristoylated AKT1 protein and differentiated for 48 hours in 
the presence of high calcium. Western blotting with an anti-HA antibody 
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confirmed exogenous AKT1 expression (Fig. 10C). As predicted, the 
differentiation-induced increase in cytokeratin 1 expression associated with 
the E5KO cells was significantly reduced in cells expressing the dominant 
negative AKT1, almost to levels observed in cells harbouring the WT 
genomes (Fig. 10C; compare lanes 4 and 5). Thus, E5 function to delay 
keratinocyte differentiation correlates with a deregulation of AKT activity. 
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Discussion 
This study provides a comprehensive analysis of E5 function during 
productive infection by HPV18; the second most prevalent high-risk type. We 
found little impact of the loss of E5 on the HPV life cycle in undifferentiated 
cells, in agreement with previous studies in keratinocyte-based model 
systems of the HPV16 and HPV31 viruses [21,22]. E5KO genomes efficiently 
established episomes and the genome-containing cells showed no growth 
disadvantage under these undifferentiated conditions. One possible 
explanation for these findings might lie in the polycistronic nature of HPV gene 
expression. Whilst recent transcript mapping studies show that E5 is present 
on abundant transcripts, it is often last in the polycistronic message and as 
such it may be inefficiently expressed in undifferentiated conditions [28]. 
Unfortunately, the absence of an effective E5 antibody makes this difficult to 
test. Alternatively, it is possible that in basal cells an additional early protein 
(e.g. E6 or E7) compensates for the loss of E5.  
 This study clearly demonstrates that E5 is required to effectively drive 
cell cycle re-entry in suprabasal cells, as judged by repression of both on-
going host cell DNA synthesis and elevated cytoplasmic cyclin B1 expression 
in the suprabasal regions of E5KO rafts. Given that viral DNA amplification is 
thought to be initiated in cells with cytoplasmic cyclin B1 [29], we studied 
whether E5 might contribute to this process and observed no reduction in the 
number of cells supporting virus genome amplification upon differentiation. In 
fact, there was no significant impact of E5 loss on HPV18 late gene 
expression, as tested by immunostaining of raft cultures for E4 and L1 
proteins. Thus, our data fit the recently described model, [23], whereby high 
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levels of viral genome amplification are necessary for late protein expression. 
Our findings are in agreement with the HPV16 E5 knockout model, which also 
saw no decrease in late protein expression [21], but are in disagreement with 
Fehrmann and colleagues who observed a significant decrease in E4 
expression in HPV31 E5KO cells [22]. Whether these differences are due to 
alternative experimental techniques or are a genuine type-specific difference 
between E5 functions awaits further study. With regards to the latter, HPV18 
is predominantly associated with adenocarcinomas of the cervix, whereas 
HPV16 and HPV31 have a strong association with squamous carcinomas; 
these differences in pathogenesis may indicate differences in life cycle 
biology. Indeed, it has recently been shown that E4 function is markedly 
different between HPV16 and HPV18 [41]. Thus, our data suggest that E5 is 
required to modulate the host cell milieu to generate cell cycle progression at 
particular stages of the productive HPV18 life cycle, but perhaps its loss can 
be compensated for by other viral protein functions, including E7, E6 or E4.   
Whilst the requirement for E5 in cell cycle progression was observed in 
the previous studies [21,22], neither study was able to provide a definitive link 
between cell cycle progression and EGFR signalling. This was surprising 
given the body of literature demonstrating a link between E5 expression and 
EGFR activation coupled with the understanding that EGFR-ERK MAPK 
signalling is a major driver of cyclin B1 expression in keratinocytes [5,6]. We 
observed enhanced EGFR expression and activity in differentiated 
keratinocytes containing HPV18 genomes compared to parental control cells. 
Absence of E5 correlated with reduced suprabasal EGFR expression but had 
no impact on EGFR expressed in the basal compartment. These data are 
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consistent with the notion that E5 is not expressed and/or required in basal 
cells and that in these cells another HPV encoded protein increases EGFR 
expression. Through the use of siRNA depletion we were able to demonstrate 
that the increased EGFR expression is necessary for cyclin B1 expression in 
differentiating keratinocytes. Moreover, small molecule inhibitors inactivating 
the EGFR kinase domain demonstrate that an active EGFR is required for this 
process. A prevailing model for E5-mediated EGFR expression suggests a 
mechanism linked with endosome deacidification or modulation of intracellular 
endosomal trafficking, whereby activated EGFR are re-routed from a 
degradative pathway into recycling endosomes, from which they are trafficked 
back to the plasma membrane. This might be accomplished by impaired 
endosome acidification resulting from either interaction with the vacuolar 
ATPase [42], modulation of endosome maturation [43] or involve the recently 
described viroporin activity of E5 [13].  
 Proliferative signalling is also known to suppress expression of proteins 
that positively regulate epithelial differentiation. We discerned a significant 
defect in differentiation marker expression in cells harbouring the HPV18 
genomes. Despite the increase in proliferative potential in cells harbouring 
HPV16 and HPV31 genomes, no apparent differences were observed in 
differentiation marker expression in the absence of E5 expression [21,22]. 
These findings do not correspond with the disturbances in epithelial 
differentiation observed in the HPV16 E5 transgenic mouse model [19]. It is 
unclear why the HPV18 life cycle model shows such an overt differentiation 
phenotype in comparison to comparable studies of HPV16 and 31. One 
explanation might lie in the level of proliferative signalling controlled by E5 in 
Wasson  E5 and the HPV18 life cycle 
	 23	
HPV18 containing cells. Since EGFR signalling suppresses differentiation it is 
possible that HPV18 E5 is more effective at suppressing these pathways than 
E5 from other high-risk types studied to date.  
Since the KGFR pathway is a known regulator of the early stages in 
suprabasal differentiation, we tested whether manipulation of KGFR might 
contribute to the defect in differentiation observed in primary keratinocytes 
harbouring the HPV18 genome. In support of this, the KGFR pathway is 
inhibited in HaCaT cells constitutively expressing isolated HPV16 E5 [44].  
KGFR signalling was impaired in cells harbouring the WT HPV18 genomes. In 
particular, we studied the KGFR effector AKT, a serine/threonine kinase that 
regulates a number of events in suprabasal cells. Levels of AKT 
phosphorylation and kinase activity were suppressed in cells harbouring 
HPV18. We were able to demonstrate the importance of the KGFR-AKT 
pathway for differentiation using a combination of small molecule inhibitors 
and retrovirus encoded dominant active and negative AKT proteins. Notably, 
treatment of E5KO cells with a KGFR kinase inhibitor or over-expression of a 
dominant negative AKT protein compensated for the loss of E5 during 
differentiation and exhibited a similar WT HPV18 differentiation marker 
expression profile. In addition, overexpression of a dominant active AKT 
protein in cells harbouring WT viral genomes prevented the virus-associated 
delay in differentiation. Importantly, E5KO cells retain WT levels of E6 and E7 
expression, which have been previously shown to potently suppress 
keratinocyte differentiation [24,26,48-53]. These data imply that AKT is a 
critical regulatory protein in the keratinocyte differentiation program. It will be 
of great interest to identify the targets of AKT that function to regulate 
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differentiation in the context of HPV infection. One candidate is GSK3β, the 
phosphorylation of which is decreased in cells harbouring WT genomes. 
Interestingly, it has recently been shown that GSK3 β was more active in cells 
containing HPV31 [47]. Since phosphorylation of GSK3 β by AKT serves to 
inhibit the function of this protein our data corroborates these findings and 
implies that targeting of the AKT-GSK3β axis is a common feature between 
the high-risk viruses HPV18 and HPV31.  
 A number of HPV early protein knockout models have been used to 
great effect to dissect the apparent contribution made by each protein to the 
productive life cycle. A major observation from these studies is the level of 
redundancy of function, in particular between the three oncogenes. For 
example, loss of E7 impacts upon S-phase progression in suprabasal cells 
and loss of both E6 and E7 expression correlates with a dysfunctional delay to 
keratinocyte differentiation. We demonstrate that E5 also targets these 
processes. We do not believe that our observations are due to any 
disturbance in E6 and/or E7 expression in our E5 knockout model for three 
reasons. Firstly, no significant difference was observed in E6 and E7 
expression between the WT and E5KO cells. Secondly, several of our findings 
have been noted using isolated E5 expression, including S-phase progression 
[54], EGFR hyperactivation [13] and suppression of KGFR transcription 
[34,55]. Finally, the E5KO phenotype is subtler than either the E6 or E7 
knockout phenotypes. For example, we observe no impact on genome 
maintenance, seen in the absence of E6 and despite a significant reduction in 
suprabasal DNA synthesis we see no effect on viral DNA amplification or late 
protein expression, both of which are abrogated in the absence of E7. Given 
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the temporal nature of HPV protein expression it is possible that specific early 
proteins target similar pathways at distinct stages during epidermal 
differentiation. This would explain why little impact is seen in the basal cells of 
the E5KO keratinocyte based models. It is also possible that early proteins 
fulfil distinct roles in each papillomavirus type, and that each HPV type might 
modulate similar pathways using distinct early proteins targeting divergent 
host proteins. Large-scale proteomic screens of early protein binding partners 
from a range of HPV types may aid in addressing these possibilities [56].  
 This study demonstrates an unanticipated role for E5 in the 
HPV18 life cycle and identifies key epithelial pathways manipulated by this 
enigmatic oncoprotein. We show a unifying role for EGFR signalling in E5 
function both as an enhancer of cell cycle progression and a repressor of 
epithelial differentiation (Fig. 11). Given the importance of EGFR activation for 
E5 function it will be essential in the future to determine how E5 activates the 
EGFR and whether the importance of EGFR signalling is a shared feature of 
other HPV E5 proteins. Future studies should also focus on understanding the 
molecular interplay between the EGFR and KGFR pathways in HPV 
containing keratinocytes. Finally, it has been reported that E5 contributes to 
the immune evasion strategy of HPV by interfering with host MHC proteins in 
keratinocytes. Our model system provides an ideal opportunity to study this 
additional role during the productive HPV18 life cycle. 
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Materials and Methods 
Small molecule inhibitors 
The quinazolone PD153035 is a specific and highly potent inhibitor of the 
EGFR kinase domain [31]. It was added to cells at a final concentration of 1 
µM. UO126 is a selective Mek1/2 inhibitor, and is used to inhibit activation of 
ERK1/2 [32]. It was added to cells at a final concentration of 20 µM. 
PD173074 was used to inhibit the kinase domain of the FGFR kinase member 
KGFR [39] and added to cells at a final concentration of 30 nM. PD153035, 
UO126 and PD173074 were purchased from Calbiochem. 	
 
Generation of E5 knockout-HPV18 pGEMII 
pGEMII plasmid containing the complete HPV18 genome (accession number: 
NC 001357) was a gift from F. Stubenrauch (University of Tübingen, 
Germany). A translation termination codon (TTA>TAA) was engineered 
immediately after the E5 start codon by site directed mutagenesis to include a 
translation termination codon (TTA>TAA) immediately after the E5 start codon 
using mutagenic primers FwdE5stopmutant and RevE5stopmutant 
(Supplementary Table 1). Briefly, 10 ng of DNA was cycled 20 times with 240 
ng of each mutagenic primer in a 50 µl reaction containing 1x KOD PCR 
buffer, 0.3 mM of each dNTP and 1 U Thermococcus kodakaraenis KOD 
polymerase (Roche). Stbl2 cells (Invitrogen) were transformed with DpnI-
digested PCR product and used to amplify the plasmid DNA. Sequencing 
using GATC Biotech Ltd services was used to sequence the entire HPV18 
genome to confirm mutagenesis of E5 and verify that no additional nucleotide 
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changes had been generated during the mutagenesis protocol (primer 
sequences can be found in Supplementary Table 1). 
 
Cell Transfection 
The transfection of primary human foreskin keratinocytes (NHK) isolated from 
neonate foreskin tissues (ethical approval no. 06/Q1702/45 for the collection 
and use of neonate foreskin tissue) was performed in S. Roberts’ laboratory 
as described previously [26,57]. To account for donor-specific effects, cell 
lines harbouring the HPV18 genomes were generated in NHK isolated from 
two donors. Briefly, plasmids containing the wild type (WT) and E5 knock-out 
(E5KO) were digested with EcoRI to release the genome, which was then re-
circularised with T4 DNA ligase. The genomes were co-transfected with a 
plasmid encoding resistance to neomycin (pcDNA3.1, Invitrogen) into low 
passage NHK in serum free medium (Invitrogen). The cells were harvested 1 
day later and seeded onto a layer of γ-irradiated J2-3T3 fibroblasts and 
selected with G418 antibiotic in complete E medium containing 5% foetal calf 
serum (FCS, Lonza) and 5 ng/mL epidermal growth factor (BD BioSciences) 
for 8 days. Cell colonies that emerged were pooled and expanded on γ-
irradiated J2-3T3 fibroblasts in complete E medium. 
 
siRNA transfection 
A pool of 4 siRNA against EGFR (Targeting different regions of the mRNA) 
(Qiagen catalogue number GS1956) were transfected into HPV 18 containing 
primary keratinocytes using lipofectamine 2000 transfection reagent (Life 
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technologies) and incubated for 24 hours. The cells were then grown in serum 
free keratinocyte media containing 1.8mM CaCl2 for a further 48 hours. 
 
Organotypic Raft Cultures 
Keratinocytes containing HPV18 WT and E5KO genomes were grown in 
organotypic raft cultures by seeding the keratinocytes onto collagen beds 
containing J2-3T3 fibroblasts. Once confluent the collagen beds were 
transferred onto metal grids and fed from below with FCS-containing E media 
lacking EGF. The cells were allowed to stratify for 13 days before fixing with 
4% formaldehyde in E media. The rafts were paraffin-embedded and 4 µm 
tissue sections prepared (Propath UK, Ltd., Hereford, UK). Cellular DNA 
synthesis was analysed by the addition of 20 µM BrdU to the medium 16-18 
hours prior to fixation. To detect BrdU-labelled nuclei, sections were 
immunostained with a fluorescein isothiocynate-conjugated antibody specific 
for BrdU (Invitrogen). Sections were stained with haematoxylin and eosin to 
assess morphology. For analysis of involucrin (SY5, Santa Cruz 
Biotechnology (sc-21748)), cyclin B1 (H-433, Santa Cruz Biotechnology (sc-
752)), HPV18 E4 (R424, [27]), HPV18 L1 (5A3, Novacastra Laboratories), 
EGFR (R-1, Santa Cruz Biotechnology) and KGFR (H-80, Santa Cruz 
Biotechnology) protein expression, the formaldehyde-fixed raft sections were 
treated with the sodium citrate method of antigen retrieval. Briefly, sections 
were boiled in 10 mM sodium citrate with 0.05% Tween-20 for 10 minutes. 
Sections were incubated with appropriate antibodies and immune complexes 
visualized by using Alexa 488 and 594 conjugated secondary antibodies 
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(Invitrogen). The nuclei were counterstained with the DNA stain 4’,6-
diamidino-2-phenylindole (DAPI) and mounted in Prolong Gold (Invitrogen). 
To detect nuclei positive for viral DNA amplification, organotypic raft culture 
sections were probed with a biotin-conjugated HPV DNA probe specific for the 
high-risk HPV types [26] using Leica BOND-Max technology as described by 
the manufacturer (Leica Microsystems, Milton Keynes) and imaged with a 
light microscope (performed by Human Biomaterials Resource Centre 
(University of Birmingham). 
 
Southern Blot Analysis 
Total genomic DNA was extracted from cell culture by phenol-chloroform 
extraction. DNA (5 µg) was treated with Dpn1 to digest residual input DNA 
and either BglII or EcoRI to analyse the physical status of the HPV18 
genomes. There are no BglII sites in the HPV18 genome. The digested DNA 
was analysed on a 0.8% agarose gel and DNA transferred to GeneScreen™ 
nylon membrane. Complete HPV18 genome was released from the pGEMII 
backbone vector by EcoRI digestion, purified and labelled with [α-32P]-CTP. 
The membrane was incubated with this radiolabelled linear probe at 42°C 
overnight. Following washing the membrane was exposed to auto-radiograph 
film. 
 
High Calcium Differentiation Assay 
Untransfected NHK and HPV18 containing keratinocytes were grown in 
complete E media until 90% confluent. Media was changed to serum free 
keratinocyte media without supplements (SFM medium, Invitrogen) containing 
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1.8 mM calcium chloride. Cells were maintained in this media for between 48 - 
72 hours before lysis and analysis.   
 
Western Blotting 
Total protein was extracted from keratinocytes in Leeds lysis buffer [58] and 
resolved by SDS-PAGE (10-15% Tris-Glycine), transferred onto Hybond 
nitrocellulose membrane (Amersham biosciences) and probed with antibodies 
specific for phosphorylated FRS2α (3861, Cell Signaling Technology), cyclin 
B1 (H-433, Santa Cruz Biotechnology), involucrin (SY5, Santa Cruz 
Biotechnology), HPV18 E6 (G-7, Santa Cruz Biotechnology),	HPV18 E7 (8E2, 
Abcam (ab100953), AKT (9272, Cell Signaling Technology), phospho-AKT 
Ser473 (D9E, Cell Signaling Technology), HA (HA-7, Sigma H9658), 
cytokeratin 1 (Poly19056, Covance), phospho-ERK1/2 (43705, Cell Signalling 
Technology), GAPDH (G-9, Santa Cruz Biotechnology),	 phospho-GSK3α/β 
(9336, Cell Signalling Technology) and EGFR (R-1, Santa Cruz 
BiotechnologyImmunoblots were visualized with species-specific HRP 
conjugated secondary antibodies (Sigma) and ECL (Thermo/Pierce). 
 
Retrovirus transduction 
pLNCX AKT vectors (Addgene 9005, 9006 [40])	 were transfected into HEK 
293T cells with murine retrovirus envelope and GAG/polymerase plasmids 
(kindly provided by Professor Greg Towers, University College London) using 
PEI transfection reagent. After 48 hours the media was removed from the 
HEK 293T cells and added to keratinocytes for 3 hours. After this time, the 
complete E media was replaced and the cells incubated for 16 hours.  
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Quantitative Real-time PCR 
Total RNA was extracted from NHK using the E.Z.N.A. Total RNA Kit I 
(Omega Bio-Tek) according to the manufacture’s protocol. Total RNA (1 µg) 
was reverse transcribed with a mixture of random primers and oligo(dT) 
primers using the qScript™ cDNA SuperMix (Quanta Biosciences) according 
to instructions. Q-RT-PCR was performed using the QuantiFast SYBR Green 
PCR kit (Qiagen) and primers specific to KGFR (Supplementary Table 1). The 
PCR reaction was conducted on a Corbett Rotor-Gene 6000 (Qiagen) as 
follows: initial activation step for 10 min at 95°C and a three-step cycle of 
denaturation (10 sec at 95°C), annealing (15 sec at 60°C) and extension (20 
sec at 72°C) which was repeated 40 times and concluded by melting curve 
analysis. The data obtained was analysed according to the ΔΔ Ct method [59] 
using the Rotor-Gene 6000 software. U6 served as normaliser gene. 
 
Analysis of Raft staining 
Analysis of staining intensities was performed using the image J software. 
Cross sections of the raft sections were plotted using the histogram function 
on the software. Histograms represent cross sections from 5 fields of view 
from three independent experiments. 
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Figure Legends. 
Figure 1: HPV18 E5 contributes towards unscheduled host cell DNA 
synthesis upon keratinocyte differentiation. (A) Southern analysis of equal 
amounts of total DNA extracted from NHK transfected with wild-type (WT) or 
mutant (E5KO) genomes in two different donors.  DNA was digested with 
DpnI (digests input DNA) together with BglII which does not digest HPV18 
DNA or EcoRI which linearizes HPV18 genomes. (B) Detection of E6 and E7 
proteins in equal amounts of Triton-X100 detergent soluble protein lysates 
prepared from cells differentiated in high-calcium monolayer cultures.  Levels 
of GAPDH were used as a loading control. Densitometry analysis of protein 
bands was performed using ImageJ software. (C) Organotypic rafts were 
incubated with BrdU to identify nuclei positive for cellular DNA synthesis. 
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BrdU positive cells were visualised with an anti-BrdU antibody (red) and nuclei 
visualised with DAPI (blue). White dotted lines indicate the basal cell layer. 
Red scale bar represents 20 µm. Organotypic raft cultures were also stained 
with haematoxylin and eosin to observe the gross morphology of the 
epithelium. (D) Graphs showing the percentage of BrdU positive nuclei in 
basal and lower suprabasal and upper suprabasal layers. The data, shown as 
a mean with standard deviation, were derived from 15 fields of view of each 
raft and from 3 independent experiments from two donors cell lines.  
Significance as determined by Student’s t-test is shown as ** = p<0.01, *** = 
p<0.001. 
 
Figure 2: HPV18 E5 deregulates cell cycle progression in differentiated 
cells. (A) Organotypic rafts stained for cyclin B1 (green) and nuclei stained 
with DAPI (blue), white dotted lines indicate the basal cell layer. Red scale bar 
represents 20 µm. (B). Graphs showing the percentage of cyclin B1 positive 
nuclei in basal and suprabasal layers. The data, shown as a mean with 
standard deviation, were derived from 15 fields of view of each raft and from 3 
independent experiments from two donor cell lines. Significance as 
determined by Student’s t-test is shown as *** = p<0.001. (C) Lysates of NHK, 
WT and E5KO cells subjected to high calcium differentiation were analysed 
for cyclin B1 expression by immunoblotting. GAPDH served as a loading 
control.  (D) Graph showing densitometry analysis of cyclin B1 expression at 
72 hours for two donors. The data is shown as a mean and standard deviation 
from three independent experiments. Significance as determined by Student’s 
t-test is shown as * = p<0.05 and **** = p<0.0001.   
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Figure 3: HPV18 E5 function is not necessary for genome amplification 
and late protein expression in differentiating keratinocytes. (A) 
Organotypic raft cultures were probed with a biotin-conjugated HPV DNA 
specific for the high-risk HPV types to visualise genome amplification. Arrows 
indicate examples of CISH positive nuclei.  Graph represents the mean (± 
standard deviation) of CISH positive nuclei per field of view (15 fields of view 
of each raft) for two separate donors. (B and C) Organotypic rafts stained for 
E4 (red) and L1 (green), nuclei were visualised with DAPI (blue). White dotted 
lines indicate the basal cell layer. Red scale bar represents 20 µm. Images 
are representative of staining from two donors and three independent 
experiments.    
 
Figure 4: HPV18 E5 maintains EGFR expression in differentiating 
keratinocytes. (A) Organotypic rafts stained for EGFR (green), with nuclei 
stained with DAPI (blue). White dotted lines indicate the basal cell layer. Red 
scale bar represents 20 µm. Images are representative of staining from two 
donors. (B) Histogram analysis of the staining intensity from WT and E5KO 
rafts. Data was derived from 5 fields of view from three independent 
experiments and two donors. (C) Lysates of keratinocytes differentiated in 
high calcium media analysed for total EGFR expression by immunoblotting. 
GAPDH served as a loading control. Western blots are representative of three 
independent experiments in two donor lines.  
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Figure 5: HPV18 requires EGFR activation to maintain cyclin B1 
expression in differentiating cells. (A) Schematic showing the EGFR/ERK 
signalling pathway and the targets of the siRNA and inhibitors used in this 
study. Mock treated keratinocytes were differentiated in high calcium media 
and lysed after 48 hours.  In parallel, keratinocytes were treated with (B) 
scramble or EGFR specific siRNA, (C) an EGFR kinase inhibitor (2 µM 
PD153035), or (D) a Mek1/2 kinase inhibitor (20 µM UO126) during 
differentiation.  All samples were analysed for cyclin B1 and phosphorylated 
ERK1/2 expression. GAPDH served as a loading control. Representative blots 
are shown from at least three independent biological repeats from two donor 
lines.   
 
Figure 6: HPV18 E5 impairs keratinocyte differentiation.  Lysates of NHK, 
WT and E5KO keratinocytes subjected to high calcium differentiation were 
analysed for involucrin and cytokeratin 1 (K1) expression.  GAPDH served as 
a loading control. Western blots are representative of three independent 
experiments in two donor lines. 
 
Figure 7: HPV18 E5 inhibits the KGFR signalling pathway.  (A) 
Organotypic raft cultures stained for KGFR expression (red) and nuclei 
stained with DAPI (blue). White dotted lines indicate the basal cell layer. Red 
scale bar represents 20 µm. Images are representative of staining from two 
donors. (B) Histogram analysis of the staining intensity from WT and E5KO 
rafts. Data was derived from 5 fields of view from three independent 
experiments, from two donors. (C)  Graph showing relative KGFR mRNA 
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expression in differentiated WT and E5KO keratinocytes after 96 hours 
incubation in high calcium media.  Results were corrected for expression of an 
U6 loading control.  The data is shown as a mean and standard deviation 
from three independent biological repeats from two donors. Significance as 
determined by Student’s t-test is shown as ** = p<0.01. (D) Schematic 
showing the interplay between the EGFR/KGFR signalling pathway and the 
target of the inhibitor used in this study. (E) Mock-treated keratinocytes were 
differentiated in high calcium media and lysed after 48 hours.  In parallel, 
keratinocytes were treated with an EGFR kinase inhibitor (2 µM PD153035), 
during differentiation. All samples were analysed for phosphorylated FRS2α 
expression.  GAPDH served as a loading control.  Representative blots are 
shown from at least three independent biological repeats from two donor 
lines.   
 
Figure 8: HPV18 E5 inhibits downstream targets of the KGFR signalling 
pathway. (A) Schematic showing the KGFR downstream signalling pathway 
including the KGFR substrate FRS2a and downstream kinases AKT and 
GSK3β. (B) Lysates of NHK, WT and E5KO keratinocytes subjected to high 
calcium differentiation were analysed for p-AKT, total AKT and p-GSK3β. 
GAPDH served as a loading control. Western blots are representative of three 
independent experiments in two donor lines  
 
Figure 9: Pharmacological inhibition of KGFR activity compensates for 
loss of E5 and impairs keratinocyte differentiation.  (A) Schematic 
showing the KGFR signalling pathway and target of the pharmacological 
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inhibitor. (B) Control (vehicle only) keratinocytes were differentiated in high 
calcium media and lysed after 48 hours. Parallel cultures of E5KO 
keratinocytes were treated with 30 nM of a KGFR kinase inhibitor 
(PD173074). Lysates were analysed for the phosphorylated forms of FRS2α, 
AKT, GSK3α/β, cytokeratin 1 (K1) and cyclin B1 by immunoblot.  
 
Figure 10: AKT is essential for the modulation of keratinocyte 
differentiation by HPV18. (A) Schematic showing the KGFR signalling 
pathway and the effects of the dominant active (DA) and negative (DN) AKT. 
HPV18 genome containing keratinocytes were infected with empty retrovirus, 
or with retroviruses encoding DA AKT (B) or DN AKT (C). Cells were 
differentiated in high calcium media for 48 hours prior to lysis and analysed for 
expression of cytokeratin 1 (K1) to assess differentiation. Expression of the 
exogenous AKT was confirmed using an antibody against the HA epitope and 
GAPDH served as a loading control.  
 
Figure 11. Schematic model depicting the proposed role of EGFR 
signalling in the E5-mediated manipulation of proliferation and 
differentiation pathways during the virus life cycle. E5 expression results 
in enhanced EGFR surface expression and activation, through a process that 
might require endosome recycling (1). This increases ERK/MAPK activity (2), 
resulting in activation of substrates, which include cell cycle associated 
proteins e.g. cyclin B (3). EGFR can suppress keratinocyte differentiation, by 
inhibiting a number of targets including the KGFR pathway. KGFR 
transcription is suppressed in E5 expressing cells (4) and KGFR signalling is 
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markedly reduced (5). As a consequence, targets of KGFR including Akt are 
suppressed, culminating in loss of expression of a number of spinous 
associated differentiation markers e.g. cytokeratin 1 (K1) (6). As a result 
keratinocyte differentiation is impaired in cells expressing E5. 
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Supplementary Table 1 
name Sequence 5’ – 3’ Application 
FwdE5stopmutant gctgtagtaccaatatgtAatcacttatt site directed mutagenesis 
RevE5stopmutant acatattggtactacagcatatgtattac site directed mutagenesis 
HPV18 seq A atagacagccaaatacag HPV18 genome 
sequencing 
HPV18 seq B actgtgcggcgtgtagca HPV18 genome 
sequencing 
HPV18 seq C actatatcttctgcctct HPV18 genome 
sequencing 
HPV18 seq D aggtgttggccttagtgg HPV18 genome 
sequencing 
HPV18 seq E aggtgttggccttagtgg HPV18 genome 
sequencing 
HPV18 seq F attgcattgtatggtatg HPV18 genome 
sequencing 
HPV18 seq G accgaaaacggtcgggac HPV18 genome 
sequencing 
HPV18 seq H atggagttaatcatcaac HPV18 genome 
sequencing 
HPV18 seq I atagtggctatggctgtt HPV18 genome 
sequencing 
HPV18 seq J agtagtgttgcagcacta HPV18 genome 
sequencing 
KGFRfwd CAGGGGTCTCCGAGTATGAA qRT-PCR 
KGFR rev TCTAAAGGCAACCTCCGAGA qRT-PCR 
U6 fwd CTC GCT TCG GCA GCA CA qRT-PCR 
U6 rev AAC GCT TCA CGC ATT TGC qRT-PCR 
 
List of all primer sequences used in this study. 
